Zhitong Finance App News, Qiming Medical-B (02500) issued an announcement. On the date of this announcement, all remedial measures proposed by the internal control consultant have been implemented or completed. As a result, the internal control consultant issued an internal control review report on May 8, 2024 after a follow-up evaluation of the remedial measures implemented by the Group.

After considering the internal control review report and the remedial measures taken by the company, the Board of Auditors and the board of directors concluded that the remedies implemented by the company and related subsidiaries (i.e. Qiming Hong Kong, Hangzhou Qijin, Qiming US and Hangzhou Qiyi) were sufficient to address the main findings of the internal control review, and that the strengthened internal control system enabled the company to manage the relevant risks at a reasonable level. Therefore, the board of directors believes that the company has now established sufficient internal control systems to meet its obligations under the listing rules.

Furthermore, trading of the company's shares continues to be suspended.